Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600537 | 1.00 | GRM4 (0.33) | GRM4PDPK1LRRK2PDE10AADORA1 | |
| SCHEMBL26675431 | 0.80 | PDPK1 (0.49) | PDPK1ADORA1 | |
| SCHEMBL29768231 | 0.80 | PDPK1 (0.49) | PDPK1ADORA1 | |
| SCHEMBL30600542 | 0.80 | PDPK1 (0.46) | PDPK1ADORA1 | |
| SCHEMBL26675396 | 0.80 | PDPK1 (0.46) | PDPK1ADORA1 | |
| SCHEMBL29768225 | 0.74 | GRM4 (0.34) | GRM4 | |
| SCHEMBL26675423 | 0.74 | GRM4 (0.34) | GRM4 | |
| SCHEMBL2067686 | 0.68 | MBOAT4 (0.34) | LRRK2PDE10A | |
| SCHEMBL29768245 | 0.68 | AOC3 (0.32) | PDPK1 | |
| SCHEMBL26675353 | 0.68 | AOC3 (0.32) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630549-B2 | Pyrazoleamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4284797-A1 | PYRAZOLEAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-12-06 | — | — | EP | disclosed |
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2022162034-A1 | PYRAZOLEAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | P2RY1, P2RX1, P2RX5 | GRM4 3070/4885PDPK1 1700/4885LRRK2 3688/4885 |
| US-12630549-B2 | Pyrazoleamide derivatives | CYP11B2, CYP11B1, ADRA1B | GRM4 886/4885PDPK1 888/4885LRRK2 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.